If corporate-financier interests would jeopardize the peace and
stability of an entire nation to maintain a monopoly over a single
pharmaceutical - developed not even by them, but by publicly funded
research - what would these same sort of corporate-financier interests
do if the stakes were infinitely higher - say as high as pushing through
a region-wide trade deal that would give such interests monopolies not
over a single chemical compound, but over entire industries?
It is clear that elected representatives in Washington, London, and
across the rest of the European Union do not represent the interests of
those who elected them. Instead, they are clearly subject to and
instruments of corporate-financier special interests - not just from
across the pharmaceutical industry, but from a variety of industries
ranging from finance and banking to big-oil, big-ag, and big-defense.
***Read full article here***
No comments:
Post a Comment